Table 1.
List of antidiabetic drugs targeting glucagon‐like peptide‐1 receptor, glucose‐dependent insulinotropic polypeptide receptor and glucagon receptor
| Drug | Company | Stage | |
|---|---|---|---|
| GLP‐1R/GIPR | LY3298176 | Eli Lilly | Phase 2 |
| NN9709/MAR709/RG7697 | Novo Nordisk/Marcadia | Phase 2 | |
| SAR438335 | Sanofi | Phase 1 | |
| CPD86 | Eli Lilly | Pre‐clinical | |
| ZP‐I‐98 | Zealand | Pre‐clinical | |
| ZP‐DI‐70 | Zealand | Pre‐clinical | |
| GLP‐1R/GR | HM12525A | Hanmi Pharmaceuticals | Phase 2 |
| MEDI0382 | Medimmune | Phase 2 | |
| MK‐8521 | Merck | Phase 2 | |
| SAR425899 | Sanofi | Phase 2 | |
| TT‐401 | Transition Therapeutics | Phase 2 | |
| JNJ‐54728518 | Janssen Pharmaceuticals | Phase 1 | |
| NN9277 | Novo Nordisk | Phase 1 | |
| MOD‐6030/1 | Prolor/OPKO Biologics | Phase 1 | |
| ZP2929 | Zealand | Phase 1 | |
| VPD‐107 | Spitfire Pharma | Pre‐clinical | |
| GLP‐1R/GIPR/GR | HM15211 | Hanmi Pharmaceuticals | Phase 1 |
| MAR423 | Novo Nordisk/Marcadia | Phase 1 |
GLP‐1, glucagon‐like polypeptide‐1; GR, glucagon receptor; GIP, glucose‐dependent insulinotropic polypeptide.